Vestal Point Capital LP Has $910,000 Stake in MacroGenics, Inc. (NASDAQ:MGNX)

Vestal Point Capital LP trimmed its holdings in MacroGenics, Inc. (NASDAQ:MGNX) by 66.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 280,000 shares of the biopharmaceutical company’s stock after selling 550,000 shares during the period. Vestal Point Capital LP’s holdings in MacroGenics were worth $910,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Barclays PLC boosted its position in MacroGenics by 97.1% in the third quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 48,639 shares during the last quarter. XML Financial LLC lifted its stake in MacroGenics by 31.6% in the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 5,569 shares during the last quarter. SG Americas Securities LLC grew its holdings in MacroGenics by 104.5% during the fourth quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 17,577 shares during the period. Charles Schwab Investment Management Inc. increased its position in MacroGenics by 7.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 527,185 shares of the biopharmaceutical company’s stock worth $1,713,000 after buying an additional 34,420 shares during the last quarter. Finally, SPC Financial Inc. bought a new position in shares of MacroGenics during the 4th quarter worth $123,000. Hedge funds and other institutional investors own 96.89% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Barclays restated an “overweight” rating and set a $3.00 price target (down from $8.00) on shares of MacroGenics in a research note on Wednesday. Stifel Nicolaus decreased their price target on shares of MacroGenics from $6.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, May 14th. HC Wainwright decreased their target price on MacroGenics from $4.00 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 25th. Finally, StockNews.com lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Eight equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.38.

MacroGenics Stock Up 2.6%

Shares of NASDAQ MGNX opened at $1.58 on Monday. MacroGenics, Inc. has a 52 week low of $0.99 and a 52 week high of $5.77. The firm has a market cap of $99.68 million, a P/E ratio of -1.00 and a beta of 2.20. The business’s 50 day moving average price is $1.56 and its 200 day moving average price is $2.60.

MacroGenics (NASDAQ:MGNX) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.04). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The company had revenue of $13.19 million for the quarter, compared to analysts’ expectations of $9.59 million. As a group, research analysts expect that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.